Condition: Chronic Lymphocytic Leukemia · B-cell Malignancies · Sponsor: Curis, Inc.
The primary objective of the study for Cohort 1 and Cohort 2 is to assess the anticancer activity of emavusertib in combination with zanubrutinib in participants with CLL.
This description comes directly from the study's public registry record.
Ahmed Hamdy, MD · 617-503-6500 · clinicaltrials@curis.com
Always discuss trial participation with your own doctor first.
| Mt Sinai Comprehensive Cancer Center | Miami Beach, Florida, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Summit Medical Group | Florham Park, New Jersey, United States | Recruiting |
| Ohio State University Comprehensive Cancer Center | Columbus, Ohio, United States | Recruiting |
| UPMC Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | Recruiting |
| Texas Oncology - Sammons Cancer Center | Dallas, Texas, United States | Recruiting |
| IRCCS Ospedale San Raffaele | Milan, Italy | Recruiting |
| Azienda Ospedaliero Universitaria Maggiore Della Carità | Novara, Italy | Recruiting |
| Azienda Ospedale Università Padova | Padova, Italy | Recruiting |
| MD Anderson Cancer Center Madrid | Madrid, Spain | Recruiting |
| Hospital Universitario Fundación Jiménez Díaz - START MADRID | Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07271667